Search
Nelipepimut-S
go.drugbank.com/drugs/DB06226InvestigationalCategories: Enzymes and Coenzymes, Amino Acids, Peptides, and ProteinsNDX-3315
go.drugbank.com/drugs/DB18671InvestigationalNDX-3315 is an investigational radiopharmaceutical agent for the diagnosis, treatment monitoring, and management of eosinophilic esophagitis. It is a technetium-99m radiolabeled [heparin].
8-azaguanine
go.drugbank.com/drugs/DB01667ExperimentalIt functions as an antimetabolite and is easily incorporated into ribonucleic acids.
Amibegron
go.drugbank.com/drugs/DB05395InvestigationalAmibegron is an agonist for atypical beta3-adrenoceptors which inhibits intestinal motility.
Quercus acutissima whole
go.drugbank.com/drugs/DB14373InvestigationalIt is not an approved drug.
Mixtures: Forest Hand Sanitizer, Forest Hand SanitizerCyamemazine
go.drugbank.com/drugs/DB09000ExperimentalCyamemazine actually behaves like an atypical antipsychotic, due to its potent anxiolytic effects (5-HT2C) and lack of extrapyramidal side effects (5-HT2A). … Cyamemazine (Tercian), also known as cyamepromazine, is a typical antipsychotic drug of the phenothiazine class used primarily in the treatment of schizophrenia and psychosis-associated anxiety.
mRNA-3705
go.drugbank.com/drugs/DB17668InvestigationalmRNA-3705 is an investigational mRNA encoding methylmalonic CoA mutase (MUT) enzyme. Developed by Moderna TX Inc., it is being investigated for the treatment of methylmalonic academia.[A258843]
Anamorelin
go.drugbank.com/drugs/DB06645InvestigationalCategories: Amino Acids, Peptides, and Proteins, Hormones, Hormone Substitutes, and Hormone AntagonistsAstegolimab
go.drugbank.com/drugs/DB16386InvestigationalAstegolimab is under investigation in clinical trial NCT04386616 (A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia).
Categories: Amino Acids, Peptides, and ProteinsMaxAdFVIII
go.drugbank.com/drugs/DB17713ExperimentalMaxAdFVIII is an adenoviral vector that expresses the full-length human Factor VIII (hFVIII) cDNA. First developed by GenStar, it is being investigated for the treatment of hemophilia.